-
Something wrong with this record ?
Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC
B. Robesova, M. Bajerova, J. Hausnerova, J. Skrickova, M. Tomiskova, D. Dvorakova,
Language English Country Ireland
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Oncogene Proteins, Fusion chemistry genetics MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Mutagenesis, Insertional * MeSH
- Middle Aged MeSH
- Humans MeSH
- Molecular Sequence Data MeSH
- Lung Neoplasms diagnosis drug therapy genetics MeSH
- Carcinoma, Non-Small-Cell Lung diagnosis drug therapy genetics MeSH
- Pyrazoles therapeutic use MeSH
- Pyridines therapeutic use MeSH
- Radiography, Thoracic MeSH
- Base Sequence MeSH
- Sequence Analysis, DNA MeSH
- Neoplasm Staging MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
We herein present a rare case of an EML4-ALK positive patient. A 61-year-old man was diagnosed with locoregional non-small cell lung cancer (NSCLC). No EGFR mutations were detected, and therefore the ALK rearrangement was evaluated using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and the reverse transcription PCR (RT-PCR) method for EML4-ALK. All methods showed a positive result and, therefore, the patient was treated with crizotinib with a good therapeutic response. However, a detailed RT-PCR analysis and sequencing revealed an unexpected 138 bp insertion of attractin-like 1 (ATRNL1) gene into the EML4-ALK fusion gene. In our case, the positive therapeutic response suggests that ATRNL1 insertion does not affect EML4-ALK's sensitivity to crizotinib. This case shows great EML4-ALK heterogeneity and also that basic detection methods (IHC, FISH) cannot fully specify ALK rearrangement but in many cases a full specification seems to be important for an effective TKI indication, and sequencing ALK variants might contribute to optimized patient selection.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000363
- 003
- CZ-PrNML
- 005
- 20160126114253.0
- 007
- ta
- 008
- 160108s2015 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.lungcan.2015.01.002 $2 doi
- 035 __
- $a (PubMed)25601488
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Robesova, Blanka $u Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic. Electronic address: blanka.robesova@fnbrno.cz.
- 245 10
- $a Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC / $c B. Robesova, M. Bajerova, J. Hausnerova, J. Skrickova, M. Tomiskova, D. Dvorakova,
- 520 9_
- $a We herein present a rare case of an EML4-ALK positive patient. A 61-year-old man was diagnosed with locoregional non-small cell lung cancer (NSCLC). No EGFR mutations were detected, and therefore the ALK rearrangement was evaluated using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and the reverse transcription PCR (RT-PCR) method for EML4-ALK. All methods showed a positive result and, therefore, the patient was treated with crizotinib with a good therapeutic response. However, a detailed RT-PCR analysis and sequencing revealed an unexpected 138 bp insertion of attractin-like 1 (ATRNL1) gene into the EML4-ALK fusion gene. In our case, the positive therapeutic response suggests that ATRNL1 insertion does not affect EML4-ALK's sensitivity to crizotinib. This case shows great EML4-ALK heterogeneity and also that basic detection methods (IHC, FISH) cannot fully specify ALK rearrangement but in many cases a full specification seems to be important for an effective TKI indication, and sequencing ALK variants might contribute to optimized patient selection.
- 650 _2
- $a sekvence nukleotidů $7 D001483
- 650 _2
- $a nemalobuněčný karcinom plic $x diagnóza $x farmakoterapie $x genetika $7 D002289
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory plic $x diagnóza $x farmakoterapie $x genetika $7 D008175
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a molekulární sekvence - údaje $7 D008969
- 650 12
- $a inzerční mutageneze $7 D016254
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a fúzní onkogenní proteiny $x chemie $x genetika $7 D015514
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a pyrazoly $x terapeutické užití $7 D011720
- 650 _2
- $a pyridiny $x terapeutické užití $7 D011725
- 650 _2
- $a rentgendiagnostika hrudníku $7 D013902
- 650 _2
- $a sekvenční analýza DNA $7 D017422
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Bajerova, Monika $u Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Hausnerova, Jitka $u Department of Pathology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Skrickova, Jana $u Department of Respiratory Diseases and Tuberculosis, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Tomiskova, Marcela $u Department of Respiratory Diseases and Tuberculosis, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Dvorakova, Dana $u Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 773 0_
- $w MED00003160 $t Lung cancer (Amsterdam, Netherlands) $x 1872-8332 $g Roč. 87, č. 3 (2015), s. 318-20
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25601488 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20160126114417 $b ABA008
- 999 __
- $a ok $b bmc $g 1102644 $s 924569
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 87 $c 3 $d 318-20 $e 20150110 $i 1872-8332 $m Lung cancer $n Lung Cancer $x MED00003160
- LZP __
- $a Pubmed-20160108